A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer

Inclusion Criteria:

• Have a histopathologically confirmed diagnosis of metastatic gastric orgastroesophageal junction (GEJ) adenocarcinoma. All histologies of nonsquamous cellorigin including undifferentiated gastric carcinoma are eligible.
• Have not received any prior first-line systemic therapy (prior adjuvant orneo-adjuvant therapy is permitted). Participants whose disease has progressed after >12 months following the last dose of systemic treatment in the adjuvant/neoadjuvantsetting are eligible.
• Have measurable or nonmeasurable but evaluable disease determined using guidelines inResponse Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v 1.1). Baselinetumor assessment should be performed using a high resolution computed tomography (CT)scan using IV and oral contrast unless clinically contra-indicated. Magnetic resonanceimaging (MRI) is acceptable if a CT cannot be performed.
• Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group scale atbaseline.
• Have adequate organ function.
• Have baseline clinical and laboratory parameters that are consistent with therequirements prescribed in respective labels and are suitable for consideration oftreatment with capecitabine (or 5-FU) and cisplatin (for example, dihydropyrimidinedehydrogenase deficiency).
• Have an estimated life expectancy of ≥12 weeks in the judgment of the investigator.

Exclusion Criteria:

• Participants with adenocarcinoma of the esophagus are excluded.
• Participants with human epidermal growth factor receptor 2 (HER2)-positive status.
• Participants receiving chronic therapy with nonsteroidal anti-inflammatory agents.
• Have radiation therapy within 14 days prior to randomization.
• Have documented brain metastases, leptomeningeal disease or uncontrolled spinal cordcompression.
• Have significant bleeding disorders, vasculitis, or had a significant bleeding episodefrom the gastrointestinal tract within 12 weeks prior to randomization.
• Have experienced any arterial thromboembolic event, including myocardial infarction,unstable angina, cerebrovascular accident, or transient ischemic attack, within 6months prior to randomization.
• Have symptomatic congestive heart failure (New York Heart Association II-IV) orsymptomatic or poorly controlled cardiac arrhythmia.
• Have uncontrolled hypertension prior to initiating study treatment, despiteantihypertensive intervention.
• Have undergone major surgery within 28 days prior to randomization, or central venousaccess device placement within 7 days prior to first dose of study treatment, exceptif the procedure is minimally invasive (for example, introduction of peripherallyinserted central catheter [PICC] line) and the investigator does not anticipate anysignificant bleeding.
• Have a history of gastrointestinal perforation and/or fistulae within 6 months priorto randomization.
• Have a history of inflammatory bowel disease or Crohn's disease requiring medicalintervention (immunomodulatory or immunosuppressive medications or surgery) ≤12 monthsprior to randomization.
• Have an acute or subacute bowel obstruction or history of chronic diarrhea which isconsidered clinically significant in the opinion of the investigator.
• The participant has:
• cirrhosis at a level of Child-Pugh B (or worse) or
• cirrhosis (any degree) and a history of hepatic encephalopathy or clinicallymeaningful ascites resulting from cirrhosis. Clinically meaningful ascites isdefined as ascites resulting from cirrhosis and requiring ongoing treatment withdiuretics and/or paracentesis.
• Have known allergy or hypersensitivity to any components of study treatment.
• Are pregnant or lactating.